Testing preference elicitation methods in clinical case studies
Our researchers will test different methods for preference elicitation in clinical case studies. We will evaluate what patients think is relevant about their disease and its impact. We will look at which treatment options they prefer and their willingness to accept trade-offs between benefits and risks of their treatment. These methods will be evaluated at different decision points in the drug development process.
We are running clinical patient preference case studies in three disease areas, involving both patient and clinical research partners in the PREFER project: lung cancer, rheumatoid arthritis and neuromuscular disorders. PhD students working in the project and partners from the pharmaceutical industry provide an additional eight more patient preference studies covering preferences for different kinds of treatment for haemophilia, rheumatoid arthritis, diabetes, multiple myeloma, chronic obstructive pulmonary disease, chronic pain and myocardial infarction. We are also using eye-tracking techniques to see how patients respond to a preference study using a methodology called discrete choice experiments (DCE).
Want to learn more? have a look at our case study catalogue here.
We start our work with a literature review, interviews and focus group meetings with patient organisations, physicians, regulatory authorities, health technology assessment bodies, industry experts and academics on their key concerns, needs, expectations and desires on the assessment and use of patient preferences.
Clinical case studies
We are running three core PREFER patient preference studies looking at lung cancer, rheumatoid arthritis and neuromuscular disorders. Both academic and industry partners have added studies to the PREFER portfolio that will help us cover different disease areas, methods and research questions.
By the middle of 2019, we will have drafted recommendations and asked stakeholder advisory groups to test them to see how they work for other disease areas and decision points. By the middle of 2021 we expect to have a refined draft. Final recommendations will be presented in the autumn of 2021.